Inscripta Announces the First Commercial Shipment of Its Onyx™ Digital Genome Engineering Platform and Closes $150 Million in New Financing

Published on
2 months ago
Body

The financing round led by Fidelity and T. Rowe Price funds underscores vast opportunities to bring Inscripta’s CRISPR-based technology to the broader bioeconomy.

Content